YAFO Acts as Financial Advisor for SIFI S.p.A. in Establishing Joint Venture with AffaMed Therapeutics

雅法担任SIFI S.p.A. 独家财务顾问,与AffaMed Therapeutics在华成立合资公司

Transaction Overview 交易概览

• SIFI S.p.A. and AffaMed Therapeutics announce they have entered into an agreement to establish a Joint Venture.
AffaMed Therapeutics 宣布与国际领先的眼科公司 SIFI S.p.A. 达成协议,双方将在华成立合资公司。

• The Joint Venture obtains the right to develop, manufacture and commercialize premium innovative intraocular lenses ("IOLs") in the Greater China market, including Mainland China, Taiwan, Macau and Hong Kong.
该合资公司负责面向大中华区(包括中国大陆、台湾、澳门和香港)市场开发、生产和销售创新的高品质人工晶体(“IOL”)产品。

• AffaMed will provide funding for growth, and support the Joint Venture in clinical development, regulatory affairs and commercial operations, while SIFI will contribute its IP, technical and manufacturing expertise.
AffaMed 将提供运营资金,并在临床开发、法规注册和商业运营方面为合资公司提供支持,SIFI 将投入知识产权、专利和制造技术。

• The Joint Venture will have exclusive rights to SIFI's range of IOLs, including the premium innovative Mini Well®, Mini Well Toric ® and Mini Well Proxa®lines of Extended Depth of Focus ("EDOF") IOL lenses.
合资公司将拥有 SIFI 人工晶体系列产品的独家权益,相关产品包括 Mini Well®、Mini Well Toric® 和 Mini Well Proxa® 系列连续视程(“EDOF”)人工晶体。

• Press Release Link: https://www.prnewswire.com/news-releases/affamed-therapeutics-and-sifi-announce-joint-venture-to-serve-greater-china-market-301259462.html

"YAFO Capital brought local expertise and network in China, allowing for a diligent, smooth and efficient deal process, leveraged by their team’s great communication skills. Thank you YAFO team.”

-- Andrea Quaglino, CFO of SIFI

SIFI S.p.A. 的首席财务官 Andrea Quaglino 表示: “在中国,雅法资本拥有资深的本土经验、广泛的人脉渠道。雅法交易团队有良好的沟通能力。在雅法团队的不懈努力下,我们的交易才得以顺利、高效地推进。为此,我们衷心感谢雅法团队的付出!”

SHANGHAI, March 31, 2021 -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to addressing critical unmet patient need in ophthalmic, neurological and psychiatric disorders, and SIFI S.p.A. ("SIFI"), a leading international ophthalmic company, today announced they have entered into an agreement to establish a Joint Venture to develop, manufacture and commercialize premium innovative intraocular lenses ("IOLs") in the Greater China market, including China, Taiwan, Macau and Hong Kong.

2021年3月31日,中国上海,致力于满足全球眼科、神经和精神系统疾病患者需求的临床阶段创新生物药公司 AffaMed Therapeutics(以下简称 “AffaMed”)宣布与国际领先的眼科公司 SIFI S.p.A.(以下简称 “SIFI”)达成协议,双方将在华成立合资公司,负责面向大中华区(包括中国大陆、台湾、澳门和香港)市场开发、生产和销售创新的高品质人工晶体(“IOL”)产品。

The Joint Venture will have exclusive rights to SIFI's range of IOLs, including the premium innovative Mini Well®, Mini Well Toric ® and Mini Well Proxa®lines of Extended Depth of Focus ("EDOF") IOL lenses. These surgical implants represent the most advanced solutions for cataract refractive surgery, allowing correction of myopia/hyperopia, presbyopia and astigmatism resulting in spectacle-free uninterrupted high-quality vision at all distances and in all lighting conditions.

合资公司将拥有 SIFI 人工晶体系列产品的独家权益,相关产品包括 Mini Well®、Mini Well Toric® 和 Mini Well Proxa® 系列连续视程(“EDOF”)人工晶体。作为白内障屈光手术中的业内领先解决方案,上述可植入人工晶体能够有效矫正近视/远视、老花和散光,帮助病人在不同距离和光线条件下获得高质量裸眼视力。

Cataract is among the leading public health issues in China today, with the total prevalence estimated at over 100 million, but only approximately 4 million cataract surgeries are currently performed annually. As awareness and access to effective treatment options such as IOL's increases, the number of cataract surgeries in China is expected to increase by 8-10% per year, representing one of the highest growth rates globally. With its range of innovative EDOF IOLs expected to be among the most advanced and effective treatment options available to cataract patients in China, the Joint Venture between AffaMed and SIFI will target the under-served premium market for patients seeking a high level of spectacle independence, while it will also provide the highest quality mono-focal IOL products to help expand access to treatments for the wider population of patients.

白内障是中国目前主要的公共医疗问题之一,总患病人数预计超过 1 亿,但目前每年实施的白内障手术仅为 400 万例左右。随着人们对有效治疗方案(如人工晶体)的认识和获取途径的增加,预计中国的白内障手术数量将会以每年 8-10% 的速度增长,跻身全球增长率最高的国家之列。通过推出一系列极具成为理想治疗方案潜力的创新 EDOF 人工晶体,AffaMed 和 SIFI 组建的合资公司将重点针对追求更优视觉效果的高端市场,同时还将提供高质量的单焦人工晶体产品,帮助更多的患者获得更好的治疗方案。

Dr. Dayao Zhao, CEO of AffaMed commented: "The creation of our Joint Venture with SIFI marks an important milestone in strengthening the ability of AffaMed to reach more patients with the highest quality IOLs. Our development and regulatory expertise will enable the partnership to accelerate clinical development and regulatory approval timelines, and advance our mission of bringing high-quality and accessible healthcare products to meet significant unmet patient needs in the Greater China market.“

AffaMed 首席执行官赵大尧博士表示:“作为 AffaMed 业务发展的又一里程碑,与 SIFI 成立合资公司将能够通过为更多患者提供高质量人工晶体,进一步增强我们的眼科业务实力。借助在开发和法规事务方面的专业经验,AffaMed 将能够加速临床开发和法规注册审批进度,推进我们实现为大中华区市场带来优质可及的医疗产品,满足广大患者亟待解决医疗需求的使命。”

Dr. Ji Li, President and Chief Strategy Officer of AffaMed commented: "Cataract is the leading cause of blindness globally, and intraocular lens implantation is the only definitive treatment. Whereas, the annual cataract surgical rate in China reached a record high of around 3,000 procedures per million people in 2020, that level still only represents approximately one-fifth of the surgical treatment rate observed in developed countries. We are thrilled to establish this strategic partnership with SIFI to bring their world-leading and high quality innovative intraocular lens technology to patients in Greater China."

AffaMed 总裁兼首席战略官李季博士表示:“白内障是全球主要的致盲原因之一,眼内晶状体植入术则是非常有效的治疗方法。2020年,中国的白内障手术率达到每百万人约 3000例的历史新高,但这仅占发达国家手术治疗率的五分之一左右。我们很高兴能够与 SIFI 建立战略合作,将世界领先的高品质创新人工晶体技术带给大中华区的更多患者。”

"We are excited to enter into a strategic partnership with AffaMed to access the Greater China market, a significant milestone in our international expansion program." said Fabrizio Chines, Chairman and CEO of SIFI. "With its successful track record in forging alliances on innovative technologies in key therapeutic areas, AffaMed represents the partner of choice to bring our innovative solutions for cataract surgery to Chinese patients.“

SIFI董事长兼首席执行官Fabrizio Chines表示:“非常高兴能够与 AffaMed 达成战略合作,进入大中华区市场,这是我们实施国际发展战略中的一项重要里程碑。在关键治疗领域创新技术战略合作方面,AffaMed 团队拥有令人印象深刻的成功案例,是将我们白内障手术创新解决方案带给中国患者的理想合作伙伴。”

Andrea Quaglino, CFO of SIFI commented: "The creation of this Joint Venture will maximize the value of one of our key assets, leveraging on our team capabilities and global market potential of SIFI's proprietary IOL technology. Delivering value to shareholders and to a larger population of patients remains at the heart of our company's mission.”

SIFI首席财务官 Andrea Quaglino 表示:“新成立的合资公司将能够更好地发挥团队的整体实力,进一步挖掘 SIFI 专有人工晶体技术的全球市场潜力,助推我们核心资产的价值最大化,并由此践行为股东和更多患者创造价值的企业使命。”

Under the terms of the agreement, AffaMed will provide funding for growth, and support the Joint Venture in clinical development, regulatory affairs and commercial operations, while SIFI will contribute its IP, technical and manufacturing expertise.

根据协议条款,AffaMed 将提供运营资金,并在临床开发、法规注册和商业运营方面为合资公司提供支持,SIFI 将投入知识产权、专利和制造技术。

About AffaMed Therapeutics

AffaMed Therapeutics is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs in ophthalmic, neurological and psychological disorders for patients in Greater China and around the world. The leadership team of AffaMed Therapeutics has gained deep industry expertise and an extensive track record in high-quality clinical development, regulatory affairs, CMC, business development and commercial operations at leading multi-national pharmaceutical companies in China and globally. AffaMed Therapeutics was founded and funded by the CBC Group in 2019.

AffaMed Therapeutics 是一家创新生物制药公司,致力于开发和商业化具有革新价值的药物,以满足大中华地区和全球患者在眼科、神经和精神系统疾病治疗领域尚未满足的关键医疗需求。AffaMed Therapeutics 的管理团队拥有深厚的专业知识,并且在中国以及与全球领先的制药公司的高质量临床开发,法规事务,化学制造与控制(CMC),业务发展和运营方面拥有众多成功案例。AffaMed Therapeutics 由康桥资本于2019年投资创立。

About SIFI S.p.A

SIFI is a leading ophthalmic company, headquartered in Italy, focusing on eye care since 1935. SIFI develops, manufactures and markets innovative therapeutic solutions for patients with ophthalmic diseases. SIFI is committed to improve patients' quality of life through its R&D efforts, exporting products to more than 20 countries worldwide with commercial operations in Italy, Spain, France, Romania, Mexico and Turkey. Since 2015 SIFI is backed by 21 Invest, a private equity firm founded by Alessandro Benetton.

SIFI 是一家总部位于意大利的国际领先眼科公司,自 1935 年成立以来一直专注于眼科护理领域。SIFI 致力于面向眼科疾病患者开发、制造和销售创新治疗方案,并通过创新研发提高患者的生活品质。公司产品目前销往全球 20 多个国家和地区,并在意大利、西班牙、法国、罗马尼亚、墨西哥和土耳其经营业务。Alessandro Benetton 先生创立的私募股权公司 21 Invest 于 2015 年参与投资 SIFI。

About YAFO Life Science 雅法全球医疗

YAFO Life Science (YLS) is the healthcare division of YAFO Capital, which is focused on helping leading U.S. and European biopharma and medtech companies to successfully enter the Asian market, especially in China and Japan. YLS also helps domestic pharma companies in global market research, targeting, and negotiation. Along with our local partners, YLS is dedicated to bridging the gap between global medical technologies and the Asian market. For more information regarding YAFO, go to: www.yafocapital.com

雅法全球医疗(YAFO Life Science)是雅法资本旗下的医疗大健康部门,专注于帮助具有“中国角度”的海外医药、医疗器械企业在中国的融资、授权和战略合作;为中国医疗企业提供产品全球授权、海外市场研究服务,寻找海外投资并购标的,及产品商业合作。雅法全球医疗核心合伙人团队均为华尔街资深投行人士或具有跨国药企工作经验;雅法庞大的海外的区域合伙人团队,均具20+年医药行业及交易经验,覆盖美国、日本 、欧洲等主要全球医药创新区域。项目合作请联系:黎琦 | BD Director | 13621979227 | qli@yafocapital.com

Recent Transaction

YAFO Upcoming Events - ACCESS CHINA Forum 2021 -Summer Showcase (June 9-11, 14-18, 2021, Bio Convention Week)

雅法药通中国夏季路演活动将于2021年6月Bio Convention Week期间举行。

Please email Wendi Xiang, wxiang@yafocapital.com, if you want to present or attend our winter partnering event.